Samsung Bioepis Earlier Announced Partnership With Novartis Unit Sandoz To Commercialize Ustekinumab Biosimilar Candidate
Portfolio Pulse from Charles Gross
Samsung Bioepis has entered into a commercialization agreement with Sandoz, a unit of Novartis, for SB17, a proposed biosimilar to Stelarai (ustekinumab). This partnership aims to strengthen access to Samsung Bioepis’ immunology portfolio in the US, Canada, EEA, Switzerland, and the UK.
September 11, 2023 | 8:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis' unit Sandoz has partnered with Samsung Bioepis to commercialize a biosimilar candidate. This could potentially expand Sandoz's product portfolio and strengthen its market position.
The partnership with Samsung Bioepis allows Sandoz to commercialize a biosimilar candidate, which could potentially expand its product portfolio and strengthen its market position. This could have a positive impact on Novartis' stock in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80